Lentiviral vector‑mediated IL‑9 overexpression stimulates cell proliferation by targeting c‑myc and cyclin D1 in colitis‑associated cancer

Tian,Linglin; Li,Yuan; Chang,Ruqi; Zhang,Peng; Zhang,Jian; Huo,Lijuan

doi:10.3892/ol.2018.9567

Lentiviral vector‑mediated IL‑9 overexpression stimulates cell proliferation by targeting c‑myc and cyclin D1 in colitis‑associated cancer

Authors:
- Linglin Tian
- Yuan Li
- Ruqi Chang
- Peng Zhang
- Jian Zhang
- Lijuan Huo
View Affiliations

Affiliations: Department of Gastroenterology, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China, Clinical Medical College, Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China
Published online on: October 11, 2018 https://doi.org/10.3892/ol.2018.9567
Pages: 175-182
Copyright: © Tian et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer caused by inflammatory bowel disease is referred as colitis‑associated cancer (CAC). The mechanism underling CAC is not fully understood. In the present study, the role of interleukin‑9 (IL‑9) in CAC was examined. The current study included 12 colorectal tissue specimens and matched adjacent tissues from CAC. The expression of IL‑9 protein was examined using immunohistochemical staining. The expression of IL‑9 in cancer tissues was markedly higher compared with that in adjacent tissues. Furthermore, IL‑9 gene overexpression lentiviral vectors were constructed to overexpress IL‑9 in RKO and Caco‑2 cell lines. The role of IL‑9 in cell proliferation was investigated using a Cell Counting Kit‑8 assay, and MYC proto‑oncogene bHLH transcription factor (c‑Myc) and cyclinD1 expression levels were detected by reverse transcription‑quantitative polymerase chain reaction. Notably, IL‑9 overexpression promoted the proliferation of colonic epithelial cells by upregulating of the expression of c‑Myc and cyclinD1. In conclusion, the present results suggested that IL‑9 may exhibit an essential role in the pathogenesis of CAC, and IL‑9 promotes the proliferation of colonic epithelial RKO and Caco2 cells, partially via the upregulation of c‑Myc and cyclinD1 expression.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. doi: 10.3322/caac.21492.
2	Grivennikov SI: Insflammation and colorectal cancer: Colitis-associated neoplasia. Semin Immunopathol. 35:229–244. 2013. View Article : Google Scholar : PubMed/NCBI
3	Ordas I, Eckmann L, Talamini M, Baumgart DC and Sandborn WJ: Ulcerative colitis. Lancet. 380:1606–1619. 2012. View Article : Google Scholar : PubMed/NCBI
4	Francescone R, Hou V and Grivennikov SI: Cytokines, IBD, and colitis-associated cancer. Inflamm Bowel Dis. 21:409–418. 2015. View Article : Google Scholar : PubMed/NCBI
5	Neurath MF: Cytokines in inflammatory bowel disease. Nat Rev Immunol. 14:329–342. 2014. View Article : Google Scholar : PubMed/NCBI
6	Toiyama Y, Okugawa Y, Tanaka K, Araki T, Uchida K, Hishida A, Uchino M, Ikeuchi H, Hirota S, Kusunoki M, et al: A panel of methylated microRNA biomarkers for identifying high-risk patients with ulcerative Colitis-associated colorectal cancer. Gastroenterology. 153:1634–1646. 2017. View Article : Google Scholar : PubMed/NCBI
7	Antoniou E, Margonis GA, Angelou A, Zografos GC and Pikoulis E: Cytokine networks in animal models of colitis-associated cancer. Anticancer Res. 35:19–24. 2015.PubMed/NCBI
8	Neurath MF and Finotto S: IL-9 signaling as key driver of chronic inflammation in mucosal immunity. Cytokine Growth Factor Rev. 29:93–99. 2016. View Article : Google Scholar : PubMed/NCBI
9	Roy DN and Goswami R: IL-9 signaling Pathway: An update. Methods Mol Biol. 1585:37–50. 2017. View Article : Google Scholar : PubMed/NCBI
10	Goswami R and Kaplan MH: A brief history of IL-9. J Immunol. 186:3283–3288. 2011. View Article : Google Scholar : PubMed/NCBI
11	Gerlach K, Hwang Y, Nikolaev A, Atreya R, Dornhoff H, Steiner S, Lehr HA, Wirtz S, Vieth M, Waisman A, et al: TH9 cells that express the transcription factor PU.1 drive T cell-mediated colitis via IL-9 receptor signaling in intestinal epithelial cells. Nat Immunol. 15:676–686. 2014. View Article : Google Scholar : PubMed/NCBI
12	Kuttler F and Mai S: c-Myc, genomic instability and disease. Genome Dyn. 1:171–190. 2006. View Article : Google Scholar : PubMed/NCBI
13	Sipos F, Firneisz G and Muzes G: Therapeutic aspects of c-MYC signaling in inflammatory and cancerous colonic diseases. World J Gastroenterol. 22:7938–7950. 2016. View Article : Google Scholar : PubMed/NCBI
14	Farrell AS and Sears RC: MYC degradation. Cold Spring Harb Perspect Med. 4:doi: 10.1101/cshperspect.a014365. PubMed/NCBI
15	Robles AI, Traverso G, Zhang M, Roberts NJ, Khan MA, Joseph C, Lauwers GY, Selaru FM, Popoli M, Pittman ME, et al: Whole-exome sequencing analyses of inflammatory bowel disease-associated colorectal cancers. Gastroenterology. 150:931–943. 2016. View Article : Google Scholar : PubMed/NCBI
16	Qie S and Diehl JA: Cyclin D1, cancer progression, and opportunities in cancer treatment. J Mol Med (Berl). 94:1313–1326. 2016. View Article : Google Scholar : PubMed/NCBI
17	Kopparapu PK, Boorjian SA, Robinson BD, Downes M, Gudas LJ, Mongan NP and Persson JL: Expression of cyclin d1 and its association with disease characteristics in bladder cancer. Anticancer Res. 33:5235–5242. 2013.PubMed/NCBI
18	Mudaliar K, Tetzlaff MT, Duvic M, Ciurea A, Hymes S, Milton DR, Tsai KY, Prieto VG, Torres-Cabala CA and Curry JL: BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression. Hum Pathol. 50:79–89. 2016. View Article : Google Scholar : PubMed/NCBI
19	Ok CY, Xu-Monette ZY, Tzankov A, O'Malley DP, Montes-Moreno S, Visco C, Møller MB, Dybkaer K, Orazi A, Zu Y, et al: Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: A report from the International DLBCL Rituximab-CHOP Consortium Program. Cancer. 120:1818–1829. 2014. View Article : Google Scholar : PubMed/NCBI
20	Peurala E, Koivunen P, Haapasaari KM, Bloigu R and Jukkola-Vuorinen A: The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer. Breast Cancer Res. 15:R52013. View Article : Google Scholar : PubMed/NCBI
21	Truran PP, Johnson SJ, Bliss RD, Lennard TW and Aspinall SR: Parafibromin, galectin-3, PGP9.5, Ki67, and cyclin D1: Using an immunohistochemical panel to aid in the diagnosis of parathyroid cancer. World J Surg. 38:2845–2854. 2014. View Article : Google Scholar : PubMed/NCBI
22	Zhao W, Hu JX, Hao RM, Zhang Q, Guo JQ, Li YJ, Xie N, Liu LY, Wang PY, Zhang C and Xie SY: Induction of microRNAlet7a inhibits lung adenocarcinoma cell growth by regulating cyclin D1. Oncol Rep. 40:1843–1854. 2018.PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Koch S, Sopel N and Finotto S: Th9 and other IL-9-producing cells in allergic asthma. Semin Immunopathol. 39:55–68. 2017. View Article : Google Scholar : PubMed/NCBI
25	Fischer M, Bijman M, Molin D, Cormont F, Uyttenhove C, van Snick J, Sundström C, Enblad G and Nilsson G: Increased serum levels of interleukin-9 correlate to negative prognostic factors in Hodgkin's lymphoma. Leukemia. 17:2513–2516. 2003. View Article : Google Scholar : PubMed/NCBI
26	Lemoli RM, Fortuna A, Tafuri A, Fogli M, Amabile M, Grande A, Ricciardi MR, Petrucci MT, Bonsi L, Bagnara G, et al: Interleukin-9 stimulates the proliferation of human myeloid leukemic cells. Blood. 87:3852–3859. 1996.PubMed/NCBI
27	Weigmann B and Neurath MF: Th9 cells in inflammatory bowel diseases. Semin Immunopathol. 39:89–95. 2017. View Article : Google Scholar : PubMed/NCBI
28	Ye ZJ, Zhou Q, Yin W, Yuan ML, Yang WB, Xiong XZ, Zhang JC and Shi HZ: Differentiation and immune regulation of IL-9-producing CD4+ T cells in malignant pleural effusion. Am J Respir Crit Care Med. 186:1168–1179. 2012. View Article : Google Scholar : PubMed/NCBI
29	Casey SC, Baylot V and Felsher DW: The MYC oncogene is a global regulator of the immune response. Blood. 131:2007–2015. 2018. View Article : Google Scholar : PubMed/NCBI
30	Jin M, Inoue S, Umemura T, Moriya J, Arakawa M, Nagashima K and Kato H: Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II. Lung cancer. 34:207–218. 2001. View Article : Google Scholar : PubMed/NCBI
31	Shamma A, Doki Y, Shiozaki H, Tsujinaka T, Yamamoto M, Inoue M, Yano M and Monden M: Cyclin D1 overexpression in esophageal dysplasia: A possible biomarker for carcinogenesis of esophageal squamous cell carcinoma. Int J Oncol. 16:261–266. 2000.PubMed/NCBI
32	Bartkova J, Lukas J, Muller H, Strauss M, Gusterson B and Bartek J: Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer. Cancer Res. 55:949–956. 1995.PubMed/NCBI